{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:47:01Z","timestamp":1791071221643,"version":"4.1.0"},"reference-count":163,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Probiotics &amp; Antimicro. Prot."],"DOI":"10.1007\/s12602-026-11164-x","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T11:15:33Z","timestamp":1786101333000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Live Biotherapeutic Products (LBPs) as Promising Microbiome-Based Medicines for Colorectal Cancer (CRC): Mechanistic Basis, Therapeutic Applications, and Translational Challenges"],"prefix":"10.1007","author":[{"given":"Samira","family":"Nomiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzaneh","family":"Yazdani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Heidary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shadi","family":"Tarzemani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Sadeghloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Saeedi Niasar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Tillotson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Safarpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8334-4180","authenticated-orcid":false,"given":"Hamideh","family":"Raeisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"issue":"2","key":"11164_CR1","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1136\/gutjnl-2022-327736","volume":"72","author":"E Morgan","year":"2023","unstructured":"Morgan E et al (2023) Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut 72(2):338\u2013344","journal-title":"Gut"},{"issue":"1","key":"11164_CR2","doi-asserted-by":"publisher","first-page":"230","DOI":"10.4251\/wjgo.v14.i1.230","volume":"14","author":"CW Wu","year":"2022","unstructured":"Wu CW, Lui RN (2022) Early-onset colorectal cancer: Current insights and future directions. World J Gastrointest Oncol 14(1):230\u2013241","journal-title":"World J Gastrointest Oncol"},{"issue":"2","key":"11164_CR3","first-page":"89","volume":"14","author":"P Rawla","year":"2019","unstructured":"Rawla P, Sunkara T, Barsouk A (2019) Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol 14(2):89\u2013103","journal-title":"Prz Gastroenterol"},{"key":"11164_CR4","unstructured":"Research W (2018) Diet, nutrition, physical activity and colorectal cancer. Continuous Update Project Expert Report"},{"issue":"2","key":"11164_CR5","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.cgh.2018.07.012","volume":"17","author":"M Song","year":"2019","unstructured":"Song M, Chan AT (2019) Environmental factors, gut microbiota, and colorectal cancer prevention. Clin Gastroenterol Hepatol 17(2):275\u2013289","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"11164_CR6","doi-asserted-by":"publisher","first-page":"G712","DOI":"10.1152\/ajpgi.00380.2020","volume":"320","author":"AT Sougiannis","year":"2021","unstructured":"Sougiannis AT et al (2021) Understanding chemotherapy-induced intestinal mucositis and strategies to improve gut resilience. Am J Physiol Gastrointest Liver Physiol 320(5):G712\u2013g719","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"11164_CR7","doi-asserted-by":"publisher","first-page":"1190850","DOI":"10.3389\/fimmu.2023.1190850","volume":"14","author":"Y Cheng","year":"2023","unstructured":"Cheng Y et al (2023) An updated review of gastrointestinal toxicity induced by PD-1 inhibitors: from mechanisms to management. Front Immunol 14:1190850","journal-title":"Front Immunol"},{"key":"11164_CR8","doi-asserted-by":"publisher","first-page":"106857","DOI":"10.1016\/j.jff.2025.106857","volume":"129","author":"N El Omari","year":"2025","unstructured":"El Omari N et al (2025) The role of inflammation in colorectal cancer and the preventive potential of natural compounds. J Funct Foods 129:106857","journal-title":"J Funct Foods"},{"issue":"Suppl 6","key":"11164_CR9","doi-asserted-by":"publisher","first-page":"S471","DOI":"10.1093\/cid\/ciad640","volume":"77","author":"SM Anderson","year":"2023","unstructured":"Anderson SM, Sears CL (2023) The Role of the gut microbiome in cancer: A review, with special focus on colorectal neoplasia and Clostridioides difficile. Clin Infect Dis 77(Suppl 6):S471\u2013S478","journal-title":"Clin Infect Dis"},{"issue":"1","key":"11164_CR10","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu B et al (2024) Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct Target Ther 9(1):274","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"11164_CR11","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1158\/2159-8290.CD-21-0236","volume":"11","author":"L Derosa","year":"2021","unstructured":"Derosa L et al (2021) Microbiota-centered interventions: The next breakthrough in immuno-oncology? Cancer Discov 11(10):2396\u20132412","journal-title":"Cancer Discov"},{"issue":"2","key":"11164_CR12","first-page":"e22156","volume":"14","author":"A Artemev","year":"2022","unstructured":"Artemev A et al (2022) The association of microbiome dysbiosis with colorectal cancer. Cureus 14(2):e22156","journal-title":"Cureus"},{"issue":"7741","key":"11164_CR13","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41586-019-0878-z","volume":"565","author":"T Tanoue","year":"2019","unstructured":"Tanoue T et al (2019) A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature 565(7741):600\u2013605","journal-title":"Nature"},{"issue":"4","key":"11164_CR14","doi-asserted-by":"publisher","first-page":"101487","DOI":"10.1016\/j.xcrm.2024.101487","volume":"5","author":"Y Yousefi","year":"2024","unstructured":"Yousefi Y, Baines KJ, Maleki Vareki S (2024) Microbiome bacterial influencers of host immunity and response to immunotherapy. Cell Rep Med 5(4):101487","journal-title":"Cell Rep Med"},{"issue":"1","key":"11164_CR15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.gpb.2022.07.002","volume":"21","author":"Y Liu","year":"2023","unstructured":"Liu Y et al (2023) Gut microbiome in colorectal cancer: clinical diagnosis and treatment. Genom Proteom Bioinform 21(1):84\u201396","journal-title":"Genom Proteom Bioinform"},{"key":"11164_CR16","doi-asserted-by":"publisher","first-page":"8727","DOI":"10.1038\/ncomms9727","volume":"6","author":"G Nakatsu","year":"2015","unstructured":"Nakatsu G et al (2015) Gut mucosal microbiome across stages of colorectal carcinogenesis. Nat Commun 6:8727","journal-title":"Nat Commun"},{"issue":"4","key":"11164_CR17","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-019-0406-6","volume":"25","author":"J Wirbel","year":"2019","unstructured":"Wirbel J et al (2019) Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. Nat Med 25(4):679\u2013689","journal-title":"Nat Med"},{"issue":"12","key":"11164_CR18","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1136\/gutjnl-2023-329543","volume":"72","author":"W Fong","year":"2023","unstructured":"Fong W et al (2023) Lactobacillus gallinarum-derived metabolites boost anti-PD1 efficacy in colorectal cancer by inhibiting regulatory T cells through modulating IDO1\/Kyn\/AHR axis. Gut 72(12):2272\u20132285","journal-title":"Gut"},{"issue":"2","key":"11164_CR19","doi-asserted-by":"publisher","first-page":"253","DOI":"10.20892\/j.issn.2095-3941.2019.0284","volume":"17","author":"W Muriithi","year":"2020","unstructured":"Muriithi W et al (2020) ABC transporters and the hallmarks of cancer: roles in cancer aggressiveness beyond multidrug resistance. Cancer Biol Med 17(2):253\u2013269","journal-title":"Cancer Biol Med"},{"key":"11164_CR20","doi-asserted-by":"crossref","unstructured":"Chang CW et al (2020) Fecal microbiota transplantation prevents intestinal injury, upregulation of toll-like receptors, and 5-fluorouracil\/oxaliplatin-induced toxicity in colorectal cancer. Int J Mol Sci 21(2)","DOI":"10.3390\/ijms21020386"},{"issue":"12","key":"11164_CR21","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1158\/0008-5472.CAN-22-2626","volume":"83","author":"A Brevi","year":"2023","unstructured":"Brevi A, Zarrinpar A (2023) Live biotherapeutic products as cancer treatments. Cancer Res 83(12):1929\u20131932","journal-title":"Cancer Res"},{"issue":"15","key":"11164_CR22","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s40265-022-01797-x","volume":"82","author":"S Khanna","year":"2022","unstructured":"Khanna S et al (2022) Efficacy and safety of RBX2660 in PUNCH CD3, a phase iii, randomized, double-blind, placebo-controlled trial with a bayesian primary analysis for the prevention of recurrent Clostridioides difficile infection. Drugs 82(15):1527\u20131538","journal-title":"Drugs"},{"key":"11164_CR23","first-page":"27","volume":"9","author":"CS Lau","year":"2016","unstructured":"Lau CS, Chamberlain RS (2016) Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Int J Gen Med 9:27\u201337","journal-title":"Int J Gen Med"},{"issue":"5","key":"11164_CR24","doi-asserted-by":"publisher","first-page":"957","DOI":"10.3390\/cancers13050957","volume":"13","author":"Y Yoon","year":"2021","unstructured":"Yoon Y et al (2021) Bifidobacterium strain-specific enhances the efficacy of cancer therapeutics in tumor-bearing mice. Cancers (Basel) 13(5):957","journal-title":"Cancers (Basel)"},{"key":"11164_CR25","doi-asserted-by":"publisher","first-page":"102315","DOI":"10.1016\/j.eclinm.2023.102315","volume":"66","author":"W Zhao","year":"2023","unstructured":"Zhao W et al (2023) Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215). EClinicalMedicine 66:102315","journal-title":"EClinicalMedicine"},{"key":"11164_CR26","doi-asserted-by":"crossref","unstructured":"Flickinger JC Jr., Rodeck U, Snook AE (2018) Listeria monocytogenes as a vector for cancer immunotherapy: current understanding and progress. Vaccines (Basel) 6(3)","DOI":"10.3390\/vaccines6030048"},{"issue":"1","key":"11164_CR27","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1038\/s41467-020-15508-1","volume":"11","author":"MR Charbonneau","year":"2020","unstructured":"Charbonneau MR et al (2020) Developing a new class of engineered live bacterial therapeutics to treat human diseases. Nat Commun 11(1):1738","journal-title":"Nat Commun"},{"issue":"12","key":"11164_CR28","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1007\/s10482-020-01474-7","volume":"113","author":"EZ Gomaa","year":"2020","unstructured":"Gomaa EZ (2020) Human gut microbiota\/microbiome in health and diseases: a review. Antonie Van Leeuwenhoek 113(12):2019\u20132040","journal-title":"Antonie Van Leeuwenhoek"},{"key":"11164_CR29","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.3389\/fmicb.2018.01835","volume":"9","author":"ZY Kho","year":"2018","unstructured":"Kho ZY, Lal SK (2018) The human gut microbiome - a potential controller of wellness and disease. Front Microbiol 9:1835","journal-title":"Front Microbiol"},{"key":"11164_CR30","doi-asserted-by":"crossref","unstructured":"Shen Y et al (2025) Gut microbiota dysbiosis: pathogenesis, diseases, prevention, and therapy. MedComm (2020) 6(5):e70168","DOI":"10.1002\/mco2.70168"},{"issue":"1","key":"11164_CR31","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12937-025-01151-3","volume":"24","author":"DR Li","year":"2025","unstructured":"Li DR et al (2025) Dietary index for gut microbiota and risk of gastrointestinal cancer: A prospective gene-diet study. Nutr J 24(1):81","journal-title":"Nutr J"},{"key":"11164_CR32","doi-asserted-by":"publisher","first-page":"101941","DOI":"10.1016\/j.bpg.2024.101941","volume":"72","author":"W Fusco","year":"2024","unstructured":"Fusco W et al (2024) Gut microbiota in colorectal cancer: From pathogenesis to clinic. Best Pract Res Clin Gastroenterol 72:101941","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"11164_CR33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41522-017-0040-3","volume":"3","author":"JL Drewes","year":"2017","unstructured":"Drewes JL et al (2017) High-resolution bacterial 16S rRNA gene profile meta-analysis and biofilm status reveal common colorectal cancer consortia. NPJ Biofilms Microbiomes 3:34","journal-title":"NPJ Biofilms Microbiomes"},{"issue":"1","key":"11164_CR34","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s11033-024-09273-3","volume":"51","author":"S Jahani-Sherafat","year":"2024","unstructured":"Jahani-Sherafat S et al (2024) Alterations in the gut microbiota and their metabolites in human intestinal epithelial cells of patients with colorectal cancer. Mol Biol Rep 51(1):265","journal-title":"Mol Biol Rep"},{"issue":"1","key":"11164_CR35","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13099-025-00717-0","volume":"17","author":"H Raeisi","year":"2025","unstructured":"Raeisi H et al (2025) Risk factors and outcomes of Clostridioides difficile infection in patients with colorectal cancer: Critical perspective in management. Gut Pathog 17(1):44","journal-title":"Gut Pathog"},{"issue":"1","key":"11164_CR36","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41522-025-00818-3","volume":"11","author":"C Chen","year":"2025","unstructured":"Chen C et al (2025) Harnessing gut microbiota for colorectal cancer therapy: From clinical insights to therapeutic innovations. NPJ Biofilms Microbiomes 11(1):190","journal-title":"NPJ Biofilms Microbiomes"},{"key":"11164_CR37","doi-asserted-by":"crossref","unstructured":"Zhang J, Wei ZJ, Fan G (2025) Emerging understanding of gut microbiome in colorectal cancer and food-related intervention strategies. Foods 14(17)","DOI":"10.3390\/foods14173040"},{"issue":"1","key":"11164_CR38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.gpb.2017.06.002","volume":"16","author":"C Meng","year":"2018","unstructured":"Meng C et al (2018) Human Gut microbiota and gastrointestinal cancer. Genom Proteom Bioinform 16(1):33\u201349","journal-title":"Genom Proteom Bioinform"},{"issue":"7802","key":"11164_CR39","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41586-020-2080-8","volume":"580","author":"C Pleguezuelos-Manzano","year":"2020","unstructured":"Pleguezuelos-Manzano C et al (2020) Mutational signature in colorectal cancer caused by genotoxic pks(+) E. coli. Nature 580(7802):269\u2013273","journal-title":"Nature"},{"issue":"2","key":"11164_CR40","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.chom.2018.01.007","volume":"23","author":"L Chung","year":"2018","unstructured":"Chung L et al (2018) Bacteroides fragilis toxin coordinates a pro-carcinogenic inflammatory cascade via targeting of colonic epithelial cells. Cell Host Microbe 23(2):203\u2013214e5","journal-title":"Cell Host Microbe"},{"issue":"6","key":"11164_CR41","doi-asserted-by":"publisher","first-page":"e00692","DOI":"10.1128\/mBio.00692-13","volume":"4","author":"JP Zackular","year":"2013","unstructured":"Zackular JP et al (2013) The gut microbiome modulates colon tumorigenesis. mBio 4(6):e00692\u2013e00613","journal-title":"mBio"},{"key":"11164_CR42","doi-asserted-by":"crossref","unstructured":"Duizer C, de Zoete MR (2023) The role of microbiota-derived metabolites in colorectal cancer. Int J Mol Sci 24(9)","DOI":"10.3390\/ijms24098024"},{"key":"11164_CR43","doi-asserted-by":"crossref","unstructured":"Ionescu VA et al (2025) Gut microbiota and colorectal cancer: a balance between risk and protection. Int J Mol Sci 26(8)","DOI":"10.3390\/ijms26083733"},{"issue":"3","key":"11164_CR44","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1007\/s12013-025-01683-9","volume":"83","author":"F Karam","year":"2025","unstructured":"Karam F et al (2025) The Gut microbiome and colorectal cancer: an integrative review of the underlying mechanisms. Cell Biochem Biophys 83(3):2637\u20132650","journal-title":"Cell Biochem Biophys"},{"key":"11164_CR45","doi-asserted-by":"crossref","unstructured":"Thoda C, Touraki M (2025) Molecular mechanisms of probiotic action against gastrointestinal cancers. Int J Mol Sci 26(16)","DOI":"10.3390\/ijms26167857"},{"issue":"6","key":"11164_CR46","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.chom.2025.05.004","volume":"33","author":"X Ding","year":"2025","unstructured":"Ding X et al (2025) Bacteroides fragilis promotes chemoresistance in colorectal cancer, and its elimination by phage VA7 restores chemosensitivity. Cell Host Microbe 33(6):941\u2013956e10","journal-title":"Cell Host Microbe"},{"issue":"1","key":"11164_CR47","doi-asserted-by":"publisher","first-page":"2333790","DOI":"10.1080\/19490976.2024.2333790","volume":"16","author":"N Wang","year":"2024","unstructured":"Wang N et al (2024) Fusobacterium nucleatum induces chemoresistance in colorectal cancer by inhibiting pyroptosis via the Hippo pathway. Gut Microbes 16(1):2333790","journal-title":"Gut Microbes"},{"issue":"6264","key":"11164_CR48","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1126\/science.aac4255","volume":"350","author":"A Sivan","year":"2015","unstructured":"Sivan A et al (2015) Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350(6264):1084\u20131089","journal-title":"Science"},{"key":"11164_CR49","doi-asserted-by":"crossref","unstructured":"Fan P et al (2025) Predictive power of different Akkermansia phylogroups in clinical response to PD-1 blockade against non-small cell lung cancer. bioRxiv","DOI":"10.1101\/2024.08.21.608814"},{"issue":"4","key":"11164_CR50","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nm.4517","volume":"24","author":"JA Gilbert","year":"2018","unstructured":"Gilbert JA et al (2018) Current understanding of the human microbiome. Nat Med 24(4):392\u2013400","journal-title":"Nat Med"},{"issue":"1","key":"11164_CR51","doi-asserted-by":"publisher","first-page":"2412376","DOI":"10.1080\/19490976.2024.2412376","volume":"16","author":"DY Kim","year":"2024","unstructured":"Kim DY et al (2024) Gut microbiome therapy: fecal microbiota transplantation vs live biotherapeutic products. Gut Microbes 16(1):2412376","journal-title":"Gut Microbes"},{"issue":"1","key":"11164_CR52","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13099-023-00550-3","volume":"15","author":"H Raeisi","year":"2023","unstructured":"Raeisi H et al (2023) Emerging applications of phage therapy and fecal virome transplantation for treatment of Clostridioides difficile infection: challenges and perspectives. Gut Pathog 15(1):21","journal-title":"Gut Pathog"},{"key":"11164_CR53","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2147\/IDR.S419243","volume":"17","author":"L Monday","year":"2024","unstructured":"Monday L, Tillotson G, Chopra T (2024) Microbiota-based live biotherapeutic products for Clostridioides difficile Infection- the devil is in the details. Infect Drug Resist 17:623\u2013639","journal-title":"Infect Drug Resist"},{"issue":"6","key":"11164_CR54","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41579-021-00667-9","volume":"20","author":"MT Sorbara","year":"2022","unstructured":"Sorbara MT, Pamer EG (2022) Microbiome-based therapeutics. Nat Rev Microbiol 20(6):365\u2013380","journal-title":"Nat Rev Microbiol"},{"issue":"5","key":"11164_CR55","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/gutjnl-2024-334501","volume":"74","author":"CH Tseng","year":"2025","unstructured":"Tseng CH et al (2025) Development of live biotherapeutic products: a position statement of Asia-Pacific Microbiota Consortium. Gut 74(5):706\u2013713","journal-title":"Gut"},{"key":"11164_CR56","doi-asserted-by":"publisher","first-page":"1272754","DOI":"10.3389\/fmicb.2023.1272754","volume":"14","author":"I Spacova","year":"2023","unstructured":"Spacova I et al (2023) Comparing technology and regulatory landscape of probiotics as food, dietary supplements and live biotherapeutics. Front Microbiol 14:1272754","journal-title":"Front Microbiol"},{"issue":"9","key":"11164_CR57","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1038\/s12276-020-0437-6","volume":"52","author":"M Cordaillat-Simmons","year":"2020","unstructured":"Cordaillat-Simmons M, Rouanet A, Pot B (2020) Live biotherapeutic products: the importance of a defined regulatory framework. Exp Mol Med 52(9):1397\u20131406","journal-title":"Exp Mol Med"},{"key":"11164_CR58","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3389\/fmicb.2019.01047","volume":"10","author":"R Mart\u00edn","year":"2019","unstructured":"Mart\u00edn R, Langella P (2019) Emerging health concepts in the probiotics field: Streamlining the definitions. Front Microbiol 10:1047","journal-title":"Front Microbiol"},{"key":"11164_CR59","doi-asserted-by":"publisher","first-page":"921972","DOI":"10.3389\/fgene.2022.921972","volume":"13","author":"Z Schemczssen-Graeff","year":"2022","unstructured":"Schemczssen-Graeff Z, Pileggi M (2022) Probiotics and live biotherapeutic products aiming at cancer mitigation and patient recover. Front genet 13:921972","journal-title":"Front genet"},{"issue":"1","key":"11164_CR60","doi-asserted-by":"publisher","first-page":"7113","DOI":"10.1038\/s41467-024-51169-0","volume":"15","author":"T Nicola","year":"2024","unstructured":"Nicola T et al (2024) A lactobacilli-based inhaled live biotherapeutic product attenuates pulmonary neutrophilic inflammation. Nat Commun 15(1):7113","journal-title":"Nat Commun"},{"issue":"9","key":"11164_CR61","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.2217\/fmb.15.66","volume":"10","author":"ZF Chen","year":"2015","unstructured":"Chen ZF et al (2015) Probiotics Clostridium butyricum and Bacillus subtilis ameliorate intestinal tumorigenesis. Future Microbiol 10(9):1433\u20131445","journal-title":"Future Microbiol"},{"issue":"1","key":"11164_CR62","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/jvim.14851","volume":"32","author":"G Segev","year":"2018","unstructured":"Segev G et al (2018) Evaluation of the live biotherapeutic product, asymptomatic bacteriuria Escherichia coli 2\u201312, in healthy dogs and dogs with clinical recurrent uti. J Vet Intern Med 32(1):267\u2013273","journal-title":"J Vet Intern Med"},{"issue":"2","key":"11164_CR63","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1177\/1756283X11428502","volume":"5","author":"T Kelesidis","year":"2012","unstructured":"Kelesidis T, Pothoulakis C (2012) Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Th Adv Gastroenterol 5(2):111\u2013125","journal-title":"Th Adv Gastroenterol"},{"issue":"12 Suppl 2","key":"11164_CR64","doi-asserted-by":"publisher","first-page":"S283","DOI":"10.1093\/infdis\/jiaa779","volume":"223","author":"QR Ducarmon","year":"2021","unstructured":"Ducarmon QR, Kuijper EJ, Olle B (2021) Opportunities and challenges in development of live biotherapeutic products to fight infections. J Infect Dis 223(12 Suppl 2):S283\u2013S289","journal-title":"J Infect Dis"},{"key":"11164_CR65","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.2147\/IDR.S400570","volume":"16","author":"S Nagarakanti","year":"2023","unstructured":"Nagarakanti S, Orenstein R (2023) Treating Clostridioides difficile: Could microbiota-based live biotherapeutic products provide the answer? Infect Drug Resist 16:3137\u20133143","journal-title":"Infect Drug Resist"},{"issue":"12","key":"11164_CR66","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/s44320-024-00067-0","volume":"20","author":"E Frutos-Grilo","year":"2024","unstructured":"Frutos-Grilo E et al (2024) Bacterial live therapeutics for human diseases. Mol Syst Biol 20(12):1261\u20131281","journal-title":"Mol Syst Biol"},{"key":"11164_CR67","doi-asserted-by":"crossref","unstructured":"Maneira C, Chamas A, Lackner G (2025) Engineering Saccharomyces cerevisiae for medical applications. Microb Cell Fact 24(1):12","DOI":"10.1186\/s12934-024-02625-5"},{"issue":"12","key":"11164_CR68","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1016\/j.immuni.2021.11.003","volume":"54","author":"AE Overacre-Delgoffe","year":"2021","unstructured":"Overacre-Delgoffe AE et al (2021) Microbiota-specific T follicular helper cells drive tertiary lymphoid structures and anti-tumor immunity against colorectal cancer. Immunity 54(12):2812\u20132824e4","journal-title":"Immunity"},{"issue":"6","key":"11164_CR69","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.chom.2021.03.016","volume":"29","author":"C Xing","year":"2021","unstructured":"Xing C et al (2021) Microbiota regulate innate immune signaling and protective immunity against cancer. Cell Host Microbe 29(6):959\u2013974e7","journal-title":"Cell Host Microbe"},{"issue":"1","key":"11164_CR70","doi-asserted-by":"publisher","first-page":"2119054","DOI":"10.1080\/19490976.2022.2119054","volume":"14","author":"DF Zegarra Ruiz","year":"2022","unstructured":"Zegarra Ruiz DF et al (2022) Microbiota manipulation to increase macrophage IL-10 improves colitis and limits colitis-associated colorectal cancer. Gut Microbes 14(1):2119054","journal-title":"Gut Microbes"},{"issue":"26","key":"11164_CR71","doi-asserted-by":"publisher","first-page":"10462","DOI":"10.1073\/pnas.1207230109","volume":"109","author":"K Khazaie","year":"2012","unstructured":"Khazaie K et al (2012) Abating colon cancer polyposis by Lactobacillus acidophilus deficient in lipoteichoic acid. Proc Natl Acad Sci U S A 109(26):10462\u201310467","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"11164_CR72","doi-asserted-by":"publisher","first-page":"4083","DOI":"10.3390\/cancers14174083","volume":"14","author":"S Kim","year":"2022","unstructured":"Kim S et al (2022) Live Biotherapeutic Lactococcus lactis GEN3013 enhances antitumor efficacy of cancer treatment via modulation of cancer progression and immune system. Cancers (Basel) 14(17):4083","journal-title":"Cancers (Basel)"},{"issue":"2","key":"11164_CR73","doi-asserted-by":"publisher","first-page":"e0147960","DOI":"10.1371\/journal.pone.0147960","volume":"11","author":"A Tiptiri-Kourpeti","year":"2016","unstructured":"Tiptiri-Kourpeti A et al (2016) Lactobacillus casei exerts anti-proliferative effects accompanied by apoptotic cell death and up-regulation of TRAIL in colon carcinoma cells. PLoS ONE 11(2):e0147960","journal-title":"PLoS ONE"},{"issue":"4","key":"11164_CR74","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.cmet.2023.03.003","volume":"35","author":"H Chen","year":"2023","unstructured":"Chen H et al (2023) Urea cycle activation triggered by host-microbiota maladaptation driving colorectal tumorigenesis. Cell Metab 35(4):651\u2013666e7","journal-title":"Cell Metab"},{"key":"11164_CR75","first-page":"100691","volume":"20","author":"N Hiraishi","year":"2019","unstructured":"Hiraishi N et al (2019) Extract of Lactobacillus plantarum strain 06CC2 induces JNK\/p38 MAPK pathway-mediated apoptosis through endoplasmic reticulum stress in Caco2 colorectal cancer cells. Biochem Biophys Rep 20:100691","journal-title":"Biochem Biophys Rep"},{"issue":"7","key":"11164_CR76","first-page":"886","volume":"23","author":"S Alizadeh","year":"2020","unstructured":"Alizadeh S, Esmaeili A, Omidi Y (2020) Anti-cancer properties of Escherichia coli Nissle 1917 against HT-29 colon cancer cells through regulation of Bax\/Bcl-xL and AKT\/PTEN signaling pathways. Iran J Basic Med Sci 23(7):886","journal-title":"Iran J Basic Med Sci"},{"issue":"5","key":"11164_CR77","doi-asserted-by":"publisher","first-page":"e0018923","DOI":"10.1128\/spectrum.00189-23","volume":"11","author":"F Xu","year":"2023","unstructured":"Xu F et al (2023) The efficacy of prevention for colon cancer based on the microbiota therapy and the antitumor mechanisms with intervention of dietary Lactobacillus. Microbiol Spectr 11(5):e0018923","journal-title":"Microbiol Spectr"},{"key":"11164_CR78","doi-asserted-by":"publisher","first-page":"102822","DOI":"10.1016\/j.redox.2023.102822","volume":"65","author":"Y He","year":"2023","unstructured":"He Y et al (2023) Butyrate reverses ferroptosis resistance in colorectal cancer by inducing c-Fos-dependent xCT suppression. Redox Biol 65:102822","journal-title":"Redox Biol"},{"key":"11164_CR79","doi-asserted-by":"crossref","unstructured":"Dikeocha IJ et al (2022) Faecalibacterium prausnitzii ameliorates colorectal tumorigenesis and suppresses proliferation of HCT116 colorectal cancer cells. Biomedicines 10(5)","DOI":"10.3390\/biomedicines10051128"},{"issue":"6","key":"11164_CR80","doi-asserted-by":"publisher","first-page":"e0253122","DOI":"10.1128\/spectrum.02531-22","volume":"10","author":"SW Ryu","year":"2022","unstructured":"Ryu SW et al (2022) Gut Microbiota Eubacterium callanderi exerts anti-colorectal cancer activity. Microbiol Spectr 10(6):e0253122","journal-title":"Microbiol Spectr"},{"issue":"2","key":"11164_CR81","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ccell.2021.12.001","volume":"40","author":"HN Bell","year":"2022","unstructured":"Bell HN et al (2022) Reuterin in the healthy gut microbiome suppresses colorectal cancer growth through altering redox balance. Cancer Cell 40(2):185\u2013200e6","journal-title":"Cancer Cell"},{"issue":"6510","key":"11164_CR82","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1126\/science.abc3421","volume":"369","author":"LF Mager","year":"2020","unstructured":"Mager LF et al (2020) Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science 369(6510):1481\u20131489","journal-title":"Science"},{"issue":"7","key":"11164_CR83","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s42255-020-0219-4","volume":"2","author":"T Wang","year":"2020","unstructured":"Wang T et al (2020) Inosine is an alternative carbon source for CD8+-T-cell function under glucose restriction. Nat Metabolism 2(7):635\u2013647","journal-title":"Nat Metabolism"},{"issue":"9","key":"11164_CR84","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1016\/j.cell.2023.03.011","volume":"186","author":"MJ Bender","year":"2023","unstructured":"Bender MJ et al (2023) Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment. Cell 186(9):1846\u20131862e26","journal-title":"Cell"},{"issue":"18","key":"11164_CR85","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.3748\/wjg.v24.i18.1995","volume":"24","author":"MCS Mendes","year":"2018","unstructured":"Mendes MCS et al (2018) Microbiota modification by probiotic supplementation reduces colitis associated colon cancer in mice. World J Gastroenterol 24(18):1995\u20132008","journal-title":"World J Gastroenterol"},{"issue":"1","key":"11164_CR86","doi-asserted-by":"publisher","first-page":"e000145","DOI":"10.1136\/bmjgast-2017-000145","volume":"4","author":"AA Hibberd","year":"2017","unstructured":"Hibberd AA et al (2017) Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention. BMJ Open Gastroenterol 4(1):e000145","journal-title":"BMJ Open Gastroenterol"},{"key":"11164_CR87","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.3389\/fimmu.2017.01553","volume":"8","author":"E Jacouton","year":"2017","unstructured":"Jacouton E et al (2017) Probiotic Strain Lactobacillus casei BL23 Prevents Colitis-Associated Colorectal Cancer. Front Immunol 8:1553","journal-title":"Front Immunol"},{"issue":"9","key":"11164_CR88","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.3390\/biomedicines10092245","volume":"10","author":"B Smit","year":"2022","unstructured":"Smit B et al (2022) Efficacy of selected live biotherapeutic candidates to inhibit the interaction of an adhesive-invasive Escherichia coli strain with Caco-2, HT29-MTX Cells and their co-culture. Biomedicines 10(9):2245","journal-title":"Biomedicines"},{"issue":"11","key":"11164_CR89","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s12275-020-0375-y","volume":"58","author":"J An","year":"2020","unstructured":"An J, Ha E-M (2020) Lactobacillus-derived metabolites enhance the antitumor activity of 5-FU and inhibit metastatic behavior in 5-FU-resistant colorectal cancer cells by regulating claudin-1 expression. J Microbiol 58(11):967\u2013977","journal-title":"J Microbiol"},{"key":"11164_CR90","doi-asserted-by":"publisher","first-page":"772532","DOI":"10.3389\/fimmu.2021.772532","volume":"12","author":"G Gao","year":"2021","unstructured":"Gao G et al (2021) Adjunctive probiotic Lactobacillus rhamnosus Probio-M9 administration enhances the effect of anti-PD-1 antitumor therapy via restoring antibiotic-disrupted gut microbiota. Front Immunol 12:772532","journal-title":"Front Immunol"},{"issue":"5","key":"11164_CR91","doi-asserted-by":"publisher","first-page":"S","DOI":"10.1016\/S0016-5085(24)03817-4","volume":"166","author":"D Lee","year":"2024","unstructured":"Lee D et al (2024) Tu1916 labthera-002, a live biotherapeutic product, improves the FOLFOX-induced cachexia in colorectal cancer mice model through gut microbiota modulation. Gastroenterology 166(5):S\u20131469","journal-title":"Gastroenterology"},{"key":"11164_CR92","doi-asserted-by":"crossref","unstructured":"Lythgoe M et al (2023) Immune modulation and the oral live biotherapeutic product, MRx0518, in treatment-na\u00efve patients with cancer: updated safety data. Am Soc Clin Oncol","DOI":"10.1200\/JCO.2023.41.16_suppl.3145"},{"key":"11164_CR93","doi-asserted-by":"crossref","unstructured":"Lin C-S et al (2021) Preclinical monotherapeutic and anti-PD-1 synergistic anti-tumor efficacy of MNC-168, a novel human-derived live biotherapeutic product. Wolters Kluwer Health","DOI":"10.1200\/JCO.2021.39.15_suppl.e14581"},{"key":"11164_CR94","doi-asserted-by":"publisher","first-page":"874922","DOI":"10.3389\/fimmu.2022.874922","volume":"13","author":"J Huang","year":"2022","unstructured":"Huang J et al (2022) Metagenomic and metabolomic analyses reveal synergistic effects of fecal microbiota transplantation and anti-PD-1 therapy on treating colorectal cancer. Front Immunol 13:874922","journal-title":"Front Immunol"},{"issue":"6371","key":"11164_CR95","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V et al (2018) Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359(6371):97\u2013103","journal-title":"Science"},{"issue":"17","key":"11164_CR96","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.3390\/cells13171437","volume":"13","author":"NK Shakhpazyan","year":"2024","unstructured":"Shakhpazyan NK et al (2024) Exploring the role of the gut microbiota in modulating colorectal cancer immunity. Cells 13(17):1437","journal-title":"Cells"},{"issue":"10","key":"11164_CR97","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.chom.2021.08.001","volume":"29","author":"A Montalban-Arques","year":"2021","unstructured":"Montalban-Arques A et al (2021) Commensal Clostridiales strains mediate effective anti-cancer immune response against solid tumors. Cell Host Microbe 29(10):1573\u20131588 .e7","journal-title":"Cell Host Microbe"},{"issue":"6917","key":"11164_CR98","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature01322","volume":"420","author":"LM Coussens","year":"2002","unstructured":"Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917):860\u2013867","journal-title":"Nature"},{"issue":"164","key":"11164_CR99","doi-asserted-by":"publisher","first-page":"164ra159","DOI":"10.1126\/scitranslmed.3004566","volume":"4","author":"NR Blatner","year":"2012","unstructured":"Blatner NR et al (2012) Expression of RORgammat marks a pathogenic regulatory T cell subset in human colon cancer. Sci Transl Med 4(164):164ra159","journal-title":"Sci Transl Med"},{"issue":"5","key":"11164_CR100","doi-asserted-by":"publisher","first-page":"e0232930","DOI":"10.1371\/journal.pone.0232930","volume":"15","author":"A Parisa","year":"2020","unstructured":"Parisa A et al (2020) Anti-cancer effects of Bifidobacterium species in colon cancer cells and a mouse model of carcinogenesis. PLoS ONE 15(5):e0232930","journal-title":"PLoS ONE"},{"key":"11164_CR101","doi-asserted-by":"publisher","first-page":"1096551","DOI":"10.3389\/fimmu.2022.1096551","volume":"13","author":"M Wang","year":"2023","unstructured":"Wang M et al (2023) The crosstalk between the gut microbiota and tumor immunity: Implications for cancer progression and treatment outcomes. Front Immunol 13:1096551","journal-title":"Front Immunol"},{"issue":"7827","key":"11164_CR102","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41586-020-2604-2","volume":"586","author":"SE Wu","year":"2020","unstructured":"Wu SE et al (2020) Microbiota-derived metabolite promotes HDAC3 activity in the gut. Nature 586(7827):108\u2013112","journal-title":"Nature"},{"issue":"3","key":"11164_CR103","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41564-019-0649-5","volume":"5","author":"E Zagato","year":"2020","unstructured":"Zagato E et al (2020) Endogenous murine microbiota member Faecalibaculum rodentium and its human homologue protect from intestinal tumour growth. Nat Microbiol 5(3):511\u2013524","journal-title":"Nat Microbiol"},{"issue":"1","key":"11164_CR104","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12967-020-02231-0","volume":"18","author":"A Botticelli","year":"2020","unstructured":"Botticelli A et al (2020) Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment. J Transl Med 18(1):49","journal-title":"J Transl Med"},{"issue":"7809","key":"11164_CR105","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41586-020-2193-0","volume":"581","author":"C Campbell","year":"2020","unstructured":"Campbell C et al (2020) Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells. Nature 581(7809):475\u2013479","journal-title":"Nature"},{"issue":"10","key":"11164_CR106","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nrmicro3344","volume":"12","author":"P Louis","year":"2014","unstructured":"Louis P, Hold GL, Flint HJ (2014) The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol 12(10):661\u2013672","journal-title":"Nat Rev Microbiol"},{"key":"11164_CR107","doi-asserted-by":"publisher","first-page":"1314528","DOI":"10.3389\/fmicb.2024.1314528","volume":"15","author":"W Liu","year":"2024","unstructured":"Liu W et al (2024) Multispecies probiotics complex improves bile acids and gut microbiota metabolism status in an in vitro fermentation model. Front Microbiol 15:1314528","journal-title":"Front Microbiol"},{"key":"11164_CR108","doi-asserted-by":"publisher","first-page":"106357","DOI":"10.1016\/j.jff.2024.106357","volume":"120","author":"G Agolino","year":"2024","unstructured":"Agolino G et al (2024) Bile salt hydrolase: The complexity behind its mechanism in relation to lowering-cholesterol lactobacilli probiotics. J Funct Foods 120:106357","journal-title":"J Funct Foods"},{"issue":"5","key":"11164_CR109","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1124\/mol.116.105361","volume":"90","author":"O Novikov","year":"2016","unstructured":"Novikov O et al (2016) An Aryl hydrocarbon receptor-mediated amplification loop that enforces cell migration in ER-\/PR-\/Her2- human breast cancer cells. Mol Pharmacol 90(5):674\u2013688","journal-title":"Mol Pharmacol"},{"issue":"3","key":"11164_CR110","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1080\/1040841X.2023.2190392","volume":"50","author":"J Meng","year":"2024","unstructured":"Meng J, Liu S, Wu X (2024) Engineered probiotics as live biotherapeutics for diagnosis and treatment of human diseases. Crit Rev Microbiol 50(3):300\u2013314","journal-title":"Crit Rev Microbiol"},{"issue":"1","key":"11164_CR111","doi-asserted-by":"publisher","first-page":"16939","DOI":"10.1038\/s41598-020-73857-9","volume":"10","author":"C De Rudder","year":"2020","unstructured":"De Rudder C et al (2020) Lacticaseibacillus casei AMBR2 modulates the epithelial barrier function and immune response in a donor-derived nasal microbiota manner. Sci Rep 10(1):16939","journal-title":"Sci Rep"},{"issue":"1","key":"11164_CR112","first-page":"2131787","volume":"2021","author":"R Nouri","year":"2021","unstructured":"Nouri R et al (2021) Mucosa-associated escherichia coli in colorectal cancer patients and control subjects: Variations in the prevalence and attributing features. Can J Infect Dis Med Microbiol 2021(1):2131787","journal-title":"Can J Infect Dis Med Microbiol"},{"issue":"1","key":"11164_CR113","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1186\/s12967-022-03609-y","volume":"20","author":"D A\u011fag\u00fcnd\u00fcz","year":"2022","unstructured":"A\u011fag\u00fcnd\u00fcz D et al (2022) Recent developments in the probiotics as live biotherapeutic products (LBPs) as modulators of gut brain axis related neurological conditions. J Transl Med 20(1):460","journal-title":"J Transl Med"},{"issue":"2","key":"11164_CR114","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s12602-024-10398-x","volume":"17","author":"H Raeisi","year":"2025","unstructured":"Raeisi H et al (2025) Bioengineered probiotics for Clostridioides difficile infection: An overview of the challenges and potential for this new treatment approach. Probiotics Antimicrob Proteins 17(2):763\u2013780","journal-title":"Probiotics Antimicrob Proteins"},{"issue":"1","key":"11164_CR115","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/s41467-024-44776-4","volume":"15","author":"CR Gurbatri","year":"2024","unstructured":"Gurbatri CR et al (2024) Engineering tumor-colonizing E. coli Nissle 1917 for detection and treatment of colorectal neoplasia. Nat Commun 15(1):646","journal-title":"Nat Commun"},{"issue":"1","key":"11164_CR116","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13036-025-00479-y","volume":"19","author":"SG Woo","year":"2025","unstructured":"Woo SG et al (2025) Engineering probiotic Escherichia coli for inflammation-responsive indoleacetic acid production using RiboJ-enhanced genetic circuits. J Biol Eng 19(1):10","journal-title":"J Biol Eng"},{"issue":"3","key":"11164_CR117","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1053\/j.gastro.2021.11.005","volume":"162","author":"AP Gobert","year":"2022","unstructured":"Gobert AP et al (2022) Protective role of spermidine in colitis and colon carcinogenesis. Gastroenterology 162(3):813\u2013827e8","journal-title":"Gastroenterology"},{"issue":"11","key":"11164_CR118","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.3390\/metabo12111061","volume":"12","author":"C Caffaratti","year":"2022","unstructured":"Caffaratti C et al (2022) Bioengineering of Escherichia coli Nissle 1917 for production and excretion of spermidine, a key metabolite in human health. Metabolites 12(11):1061","journal-title":"Metabolites"},{"issue":"1","key":"11164_CR119","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41551-017-0181-y","volume":"2","author":"CL Ho","year":"2018","unstructured":"Ho CL et al (2018) Engineered commensal microbes for diet-mediated colorectal-cancer chemoprevention. Nat Biomed Eng 2(1):27\u201337","journal-title":"Nat Biomed Eng"},{"issue":"6","key":"11164_CR120","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1021\/acsbiomaterials.0c01405","volume":"9","author":"AM Vargason","year":"2023","unstructured":"Vargason AM, Anselmo AC (2023) Evaluation of surface modified live biotherapeutic products for oral delivery. ACS Biomater Sci Eng 9(6):2868\u20132878","journal-title":"ACS Biomater Sci Eng"},{"key":"11164_CR121","unstructured":"Vargason AM (2022) Delivery strategies for live therapeutic microbes. The University of North Carolina at Chapel Hill"},{"issue":"6","key":"11164_CR122","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.3390\/biomedicines12061163","volume":"12","author":"BC Pachane","year":"2024","unstructured":"Pachane BC, Selistre-de-Araujo HS (2024) The Role of alphavbeta3 Integrin in Cancer Therapy Resistance. Biomedicines 12(6):1163","journal-title":"Biomedicines"},{"issue":"13","key":"11164_CR123","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.7150\/jca.43826","volume":"11","author":"M Zhou","year":"2020","unstructured":"Zhou M et al (2020) Integrin \u03b1v\u03b28 serves as a novel marker of poor prognosis in colon carcinoma and regulates cell invasiveness through the activation of TGF-\u03b21. J Cancer 11(13):3803","journal-title":"J Cancer"},{"issue":"10","key":"11164_CR124","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.7150\/thno.16135","volume":"6","author":"SH Park","year":"2016","unstructured":"Park SH et al (2016) RGD peptide cell-surface display enhances the targeting and therapeutic efficacy of attenuated salmonella-mediated cancer therapy. Theranostics 6(10):1672\u20131682","journal-title":"Theranostics"},{"issue":"2","key":"11164_CR125","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1053\/j.gastro.2022.10.018","volume":"164","author":"D Chrysostomou","year":"2023","unstructured":"Chrysostomou D et al (2023) Gut microbiota modulation of efficacy and toxicity of cancer chemotherapy and immunotherapy. Gastroenterology 164(2):198\u2013213","journal-title":"Gastroenterology"},{"issue":"2","key":"11164_CR126","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.resmic.2018.11.001","volume":"170","author":"R Li","year":"2019","unstructured":"Li R et al (2019) Expressing cytotoxic compounds in Escherichia coli Nissle 1917 for tumor-targeting therapy. Res Microbiol 170(2):74\u201379","journal-title":"Res Microbiol"},{"issue":"7614","key":"11164_CR127","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nature18930","volume":"536","author":"MO Din","year":"2016","unstructured":"Din MO et al (2016) Synchronized cycles of bacterial lysis for in vivo delivery. Nature 536(7614):81\u201385","journal-title":"Nature"},{"key":"11164_CR128","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1146\/annurev-bioeng-062117-121019","volume":"20","author":"JR Bober","year":"2018","unstructured":"Bober JR, Beisel CL, Nair NU (2018) Synthetic biology approaches to engineer probiotics and members of the human microbiota for biomedical applications. Annu Rev Biomed Eng 20:277\u2013300","journal-title":"Annu Rev Biomed Eng"},{"issue":"6658","key":"11164_CR129","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1126\/science.adf3974","volume":"381","author":"RM Cooper","year":"2023","unstructured":"Cooper RM et al (2023) Engineered bacteria detect tumor DNA. Science 381(6658):682\u2013686","journal-title":"Science"},{"issue":"1","key":"11164_CR130","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s40168-021-01071-4","volume":"9","author":"Y Chung","year":"2021","unstructured":"Chung Y et al (2021) A synthetic probiotic engineered for colorectal cancer therapy modulates gut microbiota. Microbiome 9(1):122","journal-title":"Microbiome"},{"issue":"4","key":"11164_CR131","doi-asserted-by":"publisher","first-page":"495","DOI":"10.4240\/wjgs.v15.i4.495","volume":"15","author":"A Kumar","year":"2023","unstructured":"Kumar A et al (2023) Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review. World J Gastrointest Surg 15(4):495\u2013519","journal-title":"World J Gastrointest Surg"},{"issue":"1","key":"11164_CR132","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12935-021-01800-7","volume":"21","author":"C Liu","year":"2021","unstructured":"Liu C et al (2021) ABCB1 and ABCG2 restricts the efficacy of gedatolisib (PF-05212384), a PI3K inhibitor in colorectal cancer cells. Cancer Cell Int 21(1):108","journal-title":"Cancer Cell Int"},{"issue":"7","key":"11164_CR133","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1002\/jcp.26406","volume":"233","author":"HH Hsu","year":"2018","unstructured":"Hsu HH et al (2018) Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis. J Cell Physiol 233(7):5458\u20135467","journal-title":"J Cell Physiol"},{"issue":"1","key":"11164_CR134","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-022-01273-9","volume":"15","author":"Y Lu","year":"2022","unstructured":"Lu Y et al (2022) Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies. J Hematol Oncol 15(1):47","journal-title":"J Hematol Oncol"},{"issue":"3","key":"11164_CR135","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/COC.0000000000001158","volume":"48","author":"Z Qureshi","year":"2025","unstructured":"Qureshi Z et al (2025) Efficacy and safety of probiotics as adjunctive therapy in cancer treatment: A comprehensive systematic review and meta-analysis. Am J Clin Oncol 48(3):148\u2013161","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"11164_CR136","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40169-019-0225-x","volume":"8","author":"J Gong","year":"2019","unstructured":"Gong J et al (2019) The gut microbiome and response to immune checkpoint inhibitors: Preclinical and clinical strategies. Clin Transl Med 8(1):9","journal-title":"Clin Transl Med"},{"issue":"8","key":"11164_CR137","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.4014\/jmb.1605.05024","volume":"26","author":"J An","year":"2016","unstructured":"An J, Ha EM (2016) Combination therapy of Lactobacillus plantarum supernatant and 5-fluouracil increases chemosensitivity in colorectal cancer cells. J Microbiol Biotechnol 26(8):1490\u20131503","journal-title":"J Microbiol Biotechnol"},{"key":"11164_CR138","first-page":"28","volume":"26","author":"H Balfour","year":"2021","unstructured":"Balfour H (2021) Developing and delivering live biotherapeutic products. Eur Pharm Rev 26:28\u201331","journal-title":"Eur Pharm Rev"},{"key":"11164_CR139","unstructured":"De Ana CL et al (2024) 607 CONSORTIUM-IO: a phase 1 study evaluating a combination of an 11-strain bacterial consortium (VE800) and nivolumab in treatment of select refractory or metastatic cancers. BMJ Specialist J"},{"key":"11164_CR140","doi-asserted-by":"publisher","first-page":"CT246","DOI":"10.1158\/1538-7445.AM2020-CT246","volume":"80","author":"D Davar","year":"2020","unstructured":"Davar D et al (2020) Abstract CT246: Consortium-IO: A safety and efficacy study of VE800 in combination with nivolumab in previously treated patients with select advanced metastatic cancers. Cancer Res 80:CT246\u2013CT246","journal-title":"Cancer Res"},{"key":"11164_CR141","doi-asserted-by":"crossref","unstructured":"Yang B-G et al (2024) 593 First-in-human evaluation of the safety, tolerability, and gut microbial composition of a live biotherapeutic product GB104 in patients with colorectal cancer. BMJ Specialist J","DOI":"10.1136\/jitc-2024-SITC2024.0593"},{"issue":"7","key":"11164_CR142","first-page":"e42347","volume":"15","author":"X Cheng","year":"2023","unstructured":"Cheng X et al (2023) Successful treatment of pMMR MSS IVB colorectal cancer using anti-vegf and anti-pd-1 therapy in combination of gut microbiota transplantation: A case report. Cureus 15(7):e42347","journal-title":"Cureus"},{"key":"11164_CR143","doi-asserted-by":"publisher","first-page":"1441290","DOI":"10.3389\/frmbi.2024.1441290","volume":"3","author":"MTI Group","year":"2024","unstructured":"Group MTI, Barberio D (2024) Navigating regulatory and analytical challenges in live biotherapeutic product development and manufacturing. Front Microbiomes 3:1441290","journal-title":"Front Microbiomes"},{"key":"11164_CR144","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/bs.pmbts.2026.01.029","volume":"220","author":"B Das","year":"2026","unstructured":"Das B (2026) Live biotherapeutics in the clinic: Regulatory pathways, market dynamics, and future trends. Prog Mol Biol Transl Sci 220:405\u2013416","journal-title":"Prog Mol Biol Transl Sci"},{"key":"11164_CR145","doi-asserted-by":"publisher","first-page":"609722","DOI":"10.3389\/fcimb.2021.609722","volume":"11","author":"S Han","year":"2021","unstructured":"Han S et al (2021) Probiotic Gastrointestinal transit and colonization after oral administration: a long journey. Front Cell Infect Microbiol 11:609722","journal-title":"Front Cell Infect Microbiol"},{"issue":"7792","key":"11164_CR146","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1038\/d41586-020-00196-0","volume":"577","author":"N Savage","year":"2020","unstructured":"Savage N (2020) The complex relationship between drugs and the microbiome. Nature 577(7792):S10\u2013s11","journal-title":"Nature"},{"issue":"6","key":"11164_CR147","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.cell.2018.02.044","volume":"172","author":"TSB Schmidt","year":"2018","unstructured":"Schmidt TSB, Raes J, Bork P (2018) The human gut microbiome: From association to modulation. Cell 172(6):1198\u20131215","journal-title":"Cell"},{"key":"11164_CR148","doi-asserted-by":"crossref","unstructured":"Minami M et al (2022) Effect of a Bifidobacterium-containing acid-resistant microcapsule formulation on gut microbiota: a pilot study. Nutrients 14(22)","DOI":"10.3390\/nu14224829"},{"issue":"10","key":"11164_CR149","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1111\/1751-7915.14293","volume":"16","author":"W Wu","year":"2023","unstructured":"Wu W et al (2023) Akkermansia muciniphila alleviates high-fat-diet-related metabolic-associated fatty liver disease by modulating gut microbiota and bile acids. Microb Biotechnol 16(10):1924\u20131939","journal-title":"Microb Biotechnol"},{"issue":"3","key":"11164_CR150","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/mbo3.252","volume":"4","author":"Y Aiba","year":"2015","unstructured":"Aiba Y et al (2015) A highly acid-resistant novel strain of Lactobacillus johnsonii 1088 has antibacterial activity, including that against Helicobacter pylori, and inhibits gastrin-mediated acid production in mice. MicrobiologyOpen 4(3):465\u2013474","journal-title":"MicrobiologyOpen"},{"issue":"4","key":"11164_CR151","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.chom.2016.09.001","volume":"20","author":"MX Maldonado-G\u00f3mez","year":"2016","unstructured":"Maldonado-G\u00f3mez MX et al (2016) Stable engraftment of Bifidobacterium longum AH1206 in the human gut depends on individualized features of the resident microbiome. Cell Host Microbe 20(4):515\u2013526","journal-title":"Cell Host Microbe"},{"issue":"6","key":"11164_CR152","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.cell.2018.08.041","volume":"174","author":"N Zmora","year":"2018","unstructured":"Zmora N et al (2018) Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. Cell 174(6):1388\u20131405e21","journal-title":"Cell"},{"issue":"1","key":"11164_CR153","doi-asserted-by":"publisher","first-page":"2503371","DOI":"10.1080\/19490976.2025.2503371","volume":"17","author":"S Jiang","year":"2025","unstructured":"Jiang S et al (2025) Gut microbiota drives structural variation of exogenous probiotics to enhance colonization. Gut Microbes 17(1):2503371","journal-title":"Gut Microbes"},{"key":"11164_CR154","doi-asserted-by":"publisher","first-page":"99","DOI":"10.54203\/jlsb.2024.10","volume":"14","author":"E Woldegerima","year":"2024","unstructured":"Woldegerima E, Tseha B (2024) Horizontal gene transfer: the hidden hazards of genetic engineering. J Life Sci Biomed 14:99\u2013108","journal-title":"J Life Sci Biomed"},{"key":"11164_CR155","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3390\/microorganisms12020238","volume":"12","author":"A Lerner","year":"2024","unstructured":"Lerner A, Benzvi C (2024) Vojdani The potential harmful effects of genetically engineered microorganisms (GEMs) on the intestinal microbiome and public health. Microorganisms 12:238. https:\/\/doi.org\/10.3390\/microorganisms12020238","journal-title":"Microorganisms"},{"issue":"5","key":"11164_CR156","doi-asserted-by":"publisher","first-page":"468","DOI":"10.4103\/1735-5362.383703","volume":"18","author":"A Shahali","year":"2023","unstructured":"Shahali A, Soltani R, Akbari V (2023) Probiotic Lactobacillus and the potential risk of spreading antibiotic resistance: a systematic review. Res Pharm Sci 18(5):468\u2013477","journal-title":"Res Pharm Sci"},{"issue":"1","key":"11164_CR157","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/s41467-022-28163-5","volume":"13","author":"AG Rottinghaus","year":"2022","unstructured":"Rottinghaus AG et al (2022) Genetically stable CRISPR-based kill switches for engineered microbes. Nat Comm 13(1):672","journal-title":"Nat Comm"},{"issue":"7","key":"11164_CR158","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1158\/1055-9965.EPI-18-0067","volume":"27","author":"X Liu","year":"2018","unstructured":"Liu X et al (2018) Circulating exosomal miR-27a and miR-130a act as novel diagnostic and prognostic biomarkers of colorectal cancer. Cancer Epidemiol Biomarkers Prev 27(7):746\u2013754","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"11164_CR159","doi-asserted-by":"publisher","first-page":"104533","DOI":"10.1016\/j.ebiom.2023.104533","volume":"91","author":"G Gao","year":"2023","unstructured":"Gao G et al (2023) Lacticaseibacillus rhamnosus Probio-M9 enhanced the antitumor response to anti-PD-1 therapy by modulating intestinal metabolites. EBioMedicine 91:104533","journal-title":"EBioMedicine"},{"issue":"6","key":"11164_CR160","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1007\/s12325-023-02505-1","volume":"40","author":"T Lodise","year":"2023","unstructured":"Lodise T et al (2023) Cost-Effectiveness analysis of REBYOTA\u2122 (fecal microbiota, Live-jslm [FMBL]) versus standard of care for the prevention of recurrent Clostridioides difficile infection in the USA. Adv Ther 40(6):2784\u20132800","journal-title":"Adv Ther"},{"key":"11164_CR161","doi-asserted-by":"crossref","unstructured":"Jin P et al (2024) The feasibility of using pathobiome strains as live biotherapeutic products for human use. iMeta 3(3)","DOI":"10.1002\/imt2.202"},{"key":"11164_CR162","doi-asserted-by":"crossref","unstructured":"Hughes RA, Ellington AD (2017) Synthetic DNA synthesis and assembly: putting the synthetic in synthetic biology. Cold Spring Harb Perspect Biol 9(1)","DOI":"10.1101\/cshperspect.a023812"},{"issue":"1","key":"11164_CR163","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/nyas.15171","volume":"1537","author":"AS Rathore","year":"2024","unstructured":"Rathore AS et al (2024) Global outlook on affordability of biotherapeutic drugs. Ann N Y Acad Sci 1537(1):168\u2013178","journal-title":"Ann N Y Acad Sci"}],"container-title":["Probiotics and Antimicrobial Proteins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12602-026-11164-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12602-026-11164-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12602-026-11164-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T13:02:53Z","timestamp":1786107773000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12602-026-11164-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":163,"alternative-id":["11164"],"URL":"https:\/\/doi.org\/10.1007\/s12602-026-11164-x","relation":{},"ISSN":["1867-1306","1867-1314"],"issn-type":[{"value":"1867-1306","type":"print"},{"value":"1867-1314","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"5 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This declaration is not applicable.","order":1,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}